Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Trump says he is open to restrictions on contraception before backing away from the statement
Pakistani police search for gunmen who abducted bus passengers and killed 10 in the southwest
Three killed in Ethiopia shootout as regional rebellions spill into the capital
Tennessee governor signs bill requiring local officers to aid US immigration authorities
It's so hot in Mexico that howler monkeys are falling dead from the trees
Benteler Steel plans $21 million expansion, will create 49 jobs
Abu Ghraib survivors bring their torture claims to a US court
Evacuation notice lifted in Utah town downstream from cracked dam
Report says China is accelerating the forced urbanization of rural Tibetans
Germany: Parliament’s lower house to vote on gender self
Seoul AI summit opens with companies including Google, Meta, OpenAI pledging to develop AI safely
A Palestinian is killed as Israeli settlers rampage in his village and troops fire on stone